{
    "doi": "https://doi.org/10.1182/blood.V114.22.3777.3777",
    "article_title": "Novel, Potent and Selective JAK2 Inhibitors. ",
    "article_date": "November 20, 2009",
    "session_type": "MOLECULAR PHARMACOLOGY, DRUG RESISTANCE POSTER III",
    "abstract_text": "Abstract 3777 Poster Board III-713 The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferative neoplasms. Strikingly, the JAK2 V617F mutation is found in nearly all patients suffering from polycythemia vera and in roughly every second patient suffering from essential thrombocythemia and from primary myelofibrosis. Thus, JAK2 represents a promising target for the treatment of myeloproliferative disorders and considerable efforts are ongoing to discover and develop inhibitors of the kinase. Here, we report potent inhibition of JAK2 V617F and JAK2 wild type enzymes by novel small molecule inhibitors, which act in an ATP-competitive manner. The profile of a lead compound from this class will be presented that displays more than twenty-fold selectivity towards JAK2 within the JAK family, as well as excellent selectivity in broader kinase profiling. The compound blunts constitutive STAT5 phosphorylation in JAK2 V617F -bearing cells, with concomitant suppression of cell proliferation and induction of apoptosis. In vivo, the inhibitor exhibited good oral bioavailability and is efficacious in suppressing leukemic cell spreading and splenomegaly in a Ba/F3 JAK2 V617F cell-driven mouse mechanistic model as well as polycythemia and extramedullary erythropoiesis in mouse and rat models. Disclosures: Radimerski: Novartis: Employment, Equity Ownership. Baffert: Novartis: Employment. Regnier: Novartis: Employment. De Pover: Novartis: Employment. Pissot: Novartis: Employment. Gerspacher: Novartis: Employment. Brueggen: Novartis: Employment. Tavares: Novartis: Employment. Blasco: Novartis: Employment. Ledieu: Novartis: Employment. Nolan: Novartis: Employment. Ruetz: Novartis: Employment. Chene: Novartis: Employment. Erdmann: Novartis: Employment. Drueckes: Novartis: Employment. Furet: Novartis: Employment. Lang: Novartis: Employment. Trappe: Novartis: Employment. Vangrevelinghe: Novartis: Employment. Wartmann: Novartis: Employment. Hofmann: Novartis: Employment.",
    "topics": [
        "amino acids",
        "apoptosis",
        "biological availability",
        "cell proliferation",
        "disclosure",
        "employment",
        "enzymes",
        "equity",
        "erythropoiesis",
        "jak2 gene v617f"
    ],
    "author_names": [
        "Thomas Radimerski, PhD",
        "Fabienne Baffert, PhD",
        "Catherine H. Regnier, PhD",
        "Alain De Pover, PhD",
        "Carole Pissot, PhD",
        "Marc Gerspacher, PhD",
        "Josef Brueggen, PhD",
        "Gisele Tavares, PhD",
        "Francesca Blasco, PhD",
        "David Ledieu, PhD",
        "Lynda Nolan",
        "Stephan Ruetz, PhD",
        "Patrick Chene, PhD",
        "Dirk Erdmann, PhD",
        "Peter Drueckes, PhD",
        "Pascal Furet, PhD",
        "Marc Lang, PhD",
        "Joerg Trappe, PhD",
        "Eric Vangrevelinghe, PhD",
        "Markus Wartmann, PhD",
        "Francesco Hofmann, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Thomas Radimerski, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Fabienne Baffert, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Catherine H. Regnier, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alain De Pover, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carole Pissot, PhD",
            "author_affiliations": [
                "Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marc Gerspacher, PhD",
            "author_affiliations": [
                "Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Josef Brueggen, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gisele Tavares, PhD",
            "author_affiliations": [
                "Translational Medicine, Novartis Pharma AG, Basel, Switzerland, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Blasco, PhD",
            "author_affiliations": [
                "MAP, Novartis Institutes for BioMedical Research, Basel, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "David Ledieu, PhD",
            "author_affiliations": [
                "Clinical Pathology, Novartis Pharma AG, Muttenz, Switzerland, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lynda Nolan",
            "author_affiliations": [
                "Clinical Pathology, Novartis Pharma AG, Muttenz, Switzerland, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stephan Ruetz, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Patrick Chene, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Dirk Erdmann, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Peter Drueckes, PhD",
            "author_affiliations": [
                "Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pascal Furet, PhD",
            "author_affiliations": [
                "Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marc Lang, PhD",
            "author_affiliations": [
                "Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joerg Trappe, PhD",
            "author_affiliations": [
                "Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eric Vangrevelinghe, PhD",
            "author_affiliations": [
                "Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Markus Wartmann, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Hofmann, PhD",
            "author_affiliations": [
                "Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland, "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-12T15:42:24",
    "is_scraped": "1"
}